<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03633890</url>
  </required_header>
  <id_info>
    <org_study_id>2017032</org_study_id>
    <nct_id>NCT03633890</nct_id>
  </id_info>
  <brief_title>DaZhu Rhodiola Rosea Capsule for Coronary Artery Disease With Angina Pectoris</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Trial for DaZhu Rhodiola Rosea Capsule in the Treatment of Coronary Artery Disease With Angina Pectoris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Anzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu Kangyuan Pharmaceutical Co. Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Anzhen Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the efficacy and safety of traditional Chinese medicine DaZhu
      Rhodiola Rosea Capsule for treatment of coronary artery disease by observing angina symptoms,
      exercise capacity, and quality of life.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2018</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seattle Angina Questionnaire (SAQ) angina frequency</measure>
    <time_frame>week 8</time_frame>
    <description>Scored from 0 to 100, with higher scores indicating better health status</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SAQ angina stability</measure>
    <time_frame>week 8</time_frame>
    <description>Scored from 0 to 100, with higher scores indicating better health status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAQ physical limitation</measure>
    <time_frame>week 8</time_frame>
    <description>Scored from 0 to 100, with higher scores indicating better health status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAQ treatment satisfaction</measure>
    <time_frame>week 8</time_frame>
    <description>Scored from 0 to 100, with higher scores indicating better health status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAQ disease perception</measure>
    <time_frame>week 8</time_frame>
    <description>Scored from 0 to 100, with higher scores indicating better health status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walking distance by 6-minute walking test</measure>
    <time_frame>week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of angina</measure>
    <time_frame>week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual analogue scale (VAS) score</measure>
    <time_frame>week 8</time_frame>
    <description>Scored from 0 to 10, with higher scores indicating worse health status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>36-item Short Form Health Survey (SF-36) score</measure>
    <time_frame>week 8</time_frame>
    <description>Scored from 36 to 180, with higher scores indicating better health status</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>DaZhu Rhodiola Rosea Capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>DaZhu Rhodiola Rosea Simulation Capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DaZhu Rhodiola Rosea Capsule</intervention_name>
    <description>Oral administration, 4 capsules, 3 times a day, for 8 weeks</description>
    <arm_group_label>DaZhu Rhodiola Rosea Capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DaZhu Rhodiola Rosea Simulation Capsule</intervention_name>
    <description>Oral administration, 4 capsules, 3 times a day, for 8 weeks</description>
    <arm_group_label>DaZhu Rhodiola Rosea Simulation Capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 to 75 years old

          -  Coronary heart disease with grade Ⅱ or Ⅲ stable or unstable angina (≥ 2 times per
             week), or residual angina-like symptoms 1 month to 1 year post percutaneous coronary
             intervention (PCI) or 3 months to 1 year post coronary artery bypass surgery (CABG)

          -  Written informed consent

        Exclusion Criteria:

          -  Acute myocardial infarction within 1 month before admission

          -  Patients who plan to undergo revascularization in the next 3 months

          -  Congestive heart failure, acute myocarditis or pericarditis, thrombophlebitis,
             pulmonary embolism, or severe neurosis within 3 months prior to admission

          -  Patients with uncontrolled high blood pressure (systolic blood pressure greater than
             160 mmHg or diastolic blood pressure greater than 100 mmHg), severe cardiopulmonary
             insufficiency (cardiac function grade Ⅲ, Ⅳ or left ventricular ejection fraction
             (LVEF) &lt; 40%), severe arrhythmia (rapid atrial fibrillation and flutter, paroxysmal
             ventricular tachycardia, degree Ⅱ type Ⅱ and degree Ⅲ atrioventricular block, etc.)

          -  Severe liver, kidney and hematopoietic system dysfunction or psychosis (serum alanine
             aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 2 times the normal upper
             limit, or serum creatinine &gt; 1.5 times the normal upper limit)

          -  History of bleeding or treatment with warfarin

          -  Implanted pacemakers

          -  Pregnant or lactating women

          -  Allergic to study drugs

          -  Legal disability (blindness, deafness, dumbness, intellectual disability, mental
             disability, physical disability)

          -  Patients who participated in other clinical trials within 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shao-Ping Nie, MD, PhD</last_name>
    <phone>86-10-84005256</phone>
    <email>spnie@ccmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiao Wang, MD</last_name>
    <phone>86-10-84005255</phone>
    <email>spaceeye123@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Shao-Ping Nie, MD, PhD</last_name>
      <phone>86-10-84005256</phone>
      <email>spnie@ccmu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Shao-Ping Nie, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 7, 2018</study_first_submitted>
  <study_first_submitted_qc>August 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2018</study_first_posted>
  <last_update_submitted>August 14, 2018</last_update_submitted>
  <last_update_submitted_qc>August 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Anzhen Hospital</investigator_affiliation>
    <investigator_full_name>Shao-Ping Nie</investigator_full_name>
    <investigator_title>Professor of Medicine, Director, Emergency &amp; Critical Care Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

